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Pertussis, a highly contagious infective disease caused by Bor-
detella pertussis, was in the past very common among new-
borns and children, causing significant medical, social and 
economic issues burden, also due to frequent need of hospitali-
zation and high mortality. Following the introduction of vac-
cines against pertussis, the burden of the disease dramatically 
decreased, although nowadays, this disease it is still the most 
widespread among the vaccine preventable ones. First vaccine 
formulations were composed with whole cell antigen of Borde-
tella pertussis and were followed by formulations with acellu-
lar antigens (PT, FHA, PRN, FIM), that showed to have similar 
efficacy and less reactogenicity. In particular, all the acellu-
lar vaccines, regardless the number of antigenic component 
included, demonstrated good immunogenicity in clinical trials 
and high effectiveness in real world evidence studies. Never-
theless, in the recent years it has been notified an increasing 
number of cases of pertussis. 
The most recent evidence demonstrated that for an effective 
control and prevention of pertussis it is necessary to strengthen 
vaccination coverage among the whole population, providing 
primary vaccination to newborns and booster in infancy, ado-
lescence and adulthood every 10 years. Finally, vaccination of 
women at the third trimester of every pregnancy is the most 
effective intervention to protect the newborn from pertussis in 
his first months of life, before developing a protective response 
after the primary vaccination.
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Summary
Introduction
Pertussis (P) is a highly contagious infective disease 
caused by the Gram-negative bacterium Bordetella per-
tussis (Bp). Until the 1940s, P was extremely common 
among subjects of pediatric age, especially younger 
children; from the healthcare, social and economic 
points of view, it carried a heavy burden in terms of 
the number of hospitalizations and deaths [1]. Follow-
ing the introduction of a whole-cell vaccine (wP) in the 
1940s, it was thought that the problem of P had largely 
been solved. Indeed, the frequency of the disease was 
markedly reduced, at least in areas where the wP was 
widely used in the pediatric population. In the Unit-
ed States, for example, where over 265,000 cases had 
been registered in 1934, the incidence of P fell to about 
100,000 cases in 1948 and declined further to 1,200-
4,000 in the 1980s  [2]. Despite this indisputable suc-
cess, however, the use of wP did not meet with the con-
sensus that would be expected, either among healthcare 
authorities or among parents. The fact that some of the 
vaccine formulations available at the time displayed 
rather low efficacy undoubtedly aroused a certain skep-
ticism. However, what chiefly hindered the systematic 
introduction of wP into the pediatric vaccination cal-
endar was the fear that its administration might cause 
potentially severe adverse events. Over time, many of 
these concerns, such as the fear that the vaccine could 
cause chronic severe encephalopathy, were shown to 
be totally unfounded. Nevertheless, the administration 
of wP did prove to be associated with the onset of sig-
nificant local reactions and fever in about 50% of vac-
cinees  [3] and of acute systemic manifestations, such 
as convulsions and persistent crying, in a small, though 
not negligible, number of subjects [4]. The result of all 
this was twofold: on the one hand, compliance with 
vaccination became very low, and vaccination was even 
not recommended by some healthcare authorities; on 
the other, efforts were made to develop new vaccines 
that would be equally efficacious but which would elic-
it fewer, if any, untoward side-effects. 
Subsequently, it was shown that the administration of 
some components of Bp, such as pertussis toxin (PT), 
filamentous hemagglutinin (FHA), pertactin (PRN) and 
fimbrial proteins 2 and 3 (FIM), could induce a protec-
tive immune response without eliciting any noteworthy 
adverse events. This evidence led to the formulation 
and subsequent diffusion of acellular anti-pertussis (aP) 
vaccines containing from 1 to 5 of these components. 
Numerous studies have shown that aP vaccines have 
similar short-term efficacy to that of wP, but greater 
safety and tolerability [5-10]. Consequently, these vac-
cines have been endorsed by the international scientific 
community and, despite their high cost, they have been 
incorporated into the vaccination calendars of a great 
many countries, with high levels of vaccination cover-
age being achieved.
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Nevertheless, a few years after the introduction of aP 
vaccines, several epidemiological evaluations clearly 
indicated that the incidence of P was slowly, though 
steadily, rising, and had even reached higher val-
ues than those recorded in periods of widespread wP 
use  [11,  12]. This increase was seen in all pediatric 
age-groups, though it was quantitatively more evident 
among older children and adolescents and qualitatively 
more marked in infants in whom a greater proportion 
of severe cases was noted. The so-called re-emergence 
of P inevitably prompted the scientific community to 
investigate the reasons for this phenomenon. The re-
emergence of an infective disease, when appropriate 
and apparently efficacious preventive measures have 
already been implemented, may be due to several fac-
tors. Thus, efforts were made to ascertain whether the 
observed rise was real, rather than the result of a dif-
ferent modality of diagnosis or reporting of cases. At 
the same time, research was undertaken to establish 
whether the problem was directly or indirectly related 
to the aP vaccines themselves, as a result either of low-
er vaccine efficacy than that which had initially been 
demonstrated, or of a change in the microbial target 
of the vaccine. Finally, researchers tried to discover 
whether the efficacy of the various aP vaccines avail-
able differed, and whether the possible re-emergence of 
P was in some way related to a particular commercial 
preparation. Although these questions have not been 
completely clarified, the information currently avail-
able enables us to draw some conclusions that can, at 
least in part, explain the re-emergence of P, and hence 
to propose some possible solutions to the problem. The 
present analysis briefly summarizes what is currently 
known about this issue.
Have pertussis cases really increased?
For many years, P was regarded as a typical childhood 
disease characterized by very specific symptoms – of-
ten easily recognizable even by non-experts – especial-
ly classic fits of coughing. These were the cases that 
were reported, which sometimes underwent culture 
tests of microbiological secretions, and on which epi-
demiological surveys were based. Over time, however, 
it emerged that in a non-negligible number of subjects 
infected by Bp, particularly older children, adolescents 
and adults, the symptoms were very different: merely 
a persistent or chronic cough, without respiratory im-
pairment or serious systemic disease. Moreover, it was 
ascertained that, even in infants, P could have manifes-
tations other than coughing fits, such as, for example, 
apneic crises [13, 14]. The identification of these cases, 
which play a key role in the spread of the disease, has 
inevitably raised the number of cases of P reported and 
notified to the authorities responsible for epidemiologi-
cal evaluations, which means that the total number of 
forms of P diagnosed each year has risen to much high-
er values than those calculated in the past. 
In addition, improvements in laboratory techniques 
now enable Bp infections to be diagnosed much more 
easily and rapidly than was hitherto possible by means 
of classical culture methods. Indeed, current tech-
niques of molecular biology allow Bp to be detected in 
respiratory secretions and anti-PT antibodies to be de-
tected in saliva within a couple of hours [15-17]. These 
advances have led to a further increase in the number 
of cases of P notified.
Nevertheless, some studies have shown that the above-
mentioned factors alone are not sufficient to explain 
the re-emergence of P that has been observed in some 
countries, albeit to different degrees and in different 
times. This is clearly demonstrated by one such study, 
which was conducted by the World Health Organiza-
tion (WHO) in 19 countries in which data were collect-
ed for sufficiently long periods of time on the incidence 
of P, vaccine administration schedules and vaccination 
coverage, surveillance methods, the case definition 
of P, and the type of vaccine used. On applying sta-
tistical methods that minimized the impact of greater 
diagnostic accuracy, it emerged that in five of these 
countries – Australia, Chile, Portugal, the USA and the 
UK – the increase in P was real, while in the other 14 
countries the rise in the number of cases reported could 
be explained by cyclical variations in the incidence of 
the disease and by possible sampling errors. Beyond 
absolute numbers, the data which seemed to suggest a 
true quantitative and qualitative increase in P were: the 
significant rise among infants in severe cases requiring 
hospitalization or transfer to intensive care or causing 
death, and the disproportionate increase in forms of P 
diagnosed in adolescents [18]. 
The epidemiology of pertussis in Italy
Before the advent of anti-pertussis vaccination, the 
mean number of notified cases of P in Italy each year 
was 21,000. By contrast, the latest report issued by the 
European Centre for Disease Prevention and Control 
(ECDC), which refers to the period 2011-2015, quotes 
a mean of 500 cases per year [19]. Thus, in comparison 
with the pre-vaccination era, the incidence of P in Italy 
has fallen by 97.6% as a result of both vaccination and 
the use of aP vaccines (notified cases in 2015 were 503; 
Tab. I) [19, 20]. 
However, the incidence of P is probably underestimat-
ed, especially among adolescents and young adults, in 
whom the clinical picture is milder than in infants and 
whose symptoms may be confused with those of other 
respiratory conditions. Moreover, laboratory tech-
niques, which are essential to confirming the diagno-
Tab. I. Pertussis cases reported in Italy, 2011-2015.
Year 2011 2012 2013 2014 2015
Number of cases 516 489 523 670 503
From European Centre for Disease Prevention and Control, 2015 19, mod.; 
Epicentro, 2017 20, mod. 
PERTUSSIS PREVENTION
E179
sis, are not frequently implemented. Furthermore, par-
ents are the main source of the contagion of children, 
in whom the disease tends to be more severe [21, 22]. 
Notifications of cases of P by age-class in Italy in the 
period 1996-2009 are shown in Figure 1.
Short duration  
of vaccine-induced protection
The re-emergence of P forced the scientific community 
to seek possible explanations for the phenomenon. At-
tention was chiefly focused on the duration of vaccine 
efficacy and on the eventuality that the emergence of 
genetically mutated Bp strains in the proteins included 
in the aP vaccines might have blunted, or even nullified, 
vaccine efficacy.
What aroused the suspicion that aP vaccines might con-
fer only short-term protection was mainly the fact that 
a large number of cases of P were diagnosed in adoles-
cents, i.e. several years after the primary vaccination. 
However, it had long been known that neither the disease 
nor vaccination, regardless of the vaccine used (wP or 
aP), conferred permanent protection against P. Indeed, 
the immunity elicited by vaccination lasts from 4 to 12 
years, while the protection acquired after natural infec-
tion by Bp lasts 7-20 years (Tabs.  II,  III,  IV)  [23-36]. 
For this reason, several countries have for a long time 
scheduled an anti-P booster vaccination for pre-school 
children, i.e. aged 5-6 years.
The risk of contracting P is directly proportional to the 
time that has elapsed since the last vaccination. Indeed, it 
has been reported that children who receive the preschool 
booster at 4 years of age have a more than 2-fold higher 
probability of contracting P during the subsequent years 
of school than those re-vaccinated at 5 years of age [37]. 
These findings are completely in line with the results of 
a recent Italian study aimed at ascertaining the etiology 
of persistent or chronic coughing in children. The data 
gathered indicated that about 20% of the children and 
adolescents who had been affected by coughing for no 
apparent reason for at least 15 days was suffering from 
P. In over 80% of cases, the subjects had been regularly 
vaccinated with an aP vaccines and had received the pre-
school booster. In some cases, moreover, the booster had 
been administered no more than 2-3 years before the on-
set of the disease [38]. 
The different immune response elicited by the various 
aP vaccines, in comparison with that elicited by natural 
infection or wP, may explain, at least in part, the dif-
ferent duration of the protection induced. Moreover, al-
though the aP vaccines are effective in preventing the 
clinical manifestations of P, they are unable to prevent 
colonization by Bp; they therefore do not reduce the risk 
of transmission from a colonized subject to a healthy 
subject [39].
Fig. 1. Pertussis: trend in notifications in Italy, 1996-2009 (from Gabutti et al., 2012 22, mod.).
Tab. II. Studies conducted since the 1990s on the duration of protec-
tion induced by the whole-cell pertussis vaccine (wP). 
Author Year Subjects Estimated 
duration of 
protection
(years)
Country
CDC [24] 1993 225 4-6
USA 
(Massachusetts)
Ramsay [25] 1993 3,150 8 UK
Nielsen & 
Larsen [26]
1994
Not 
known
10 Denmark
He [27] 1996 3,794 5-10 Finland
Van  
Buynder [28]
1999 15,286 5-14 UK
Torvaldsen [29] 2003
Not 
known
6-9 Australia
From Wendelboe AM et al., 2015 23, mod.
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Numerous studies have shown that the levels of anti-
bodies elicited by aP vaccines against the various Bp 
antigens tend to wane rapidly [40-44]. One of the first 
studies to investigate this issue was conducted by Es-
posito et al.  [40]. These authors examined 38 children 
who had regularly received, in the first year of life, the 
recommended doses of a combined vaccine containing 
diphtheria, tetanus and hepatitis B vaccines in addition 
to a 3-component aP vaccine. Analysis of the antibodies 
against PT, FHA and PRN revealed that, 5 years after the 
last dose, very few subjects had adequate levels of spe-
cific antibodies against all the Bp antigens contained in 
the vaccine. In addition, in vitro study of the response of 
the peripheral mononucleated cells to exposure to these 
antigens revealed that a very small number of subjects 
tested had marked immunological memory. 
The different behavior of the aP and wP vaccines can 
be explained, at least in part, by the fact that each elic-
its a substantially different immune response. The wP 
vaccines induce a response that is very similar, albeit 
less intense, to that induced by natural infection. In both 
cases, there is a marked production of IgG1, IgG2 and 
IgG3 antibodies, which is indicative of a significant Th1 
response. In addition, there is a considerable Th17 re-
sponse. The aP vaccines, by contrast, regardless of the 
number of components they contain, evoke IgG1 and 
IgG4 production, but elicit a scant Th17 response; this 
suggests that the aP vaccines induce a mixed Th1/Th2 
response. These differences have been confirmed by 
studies of the CD4+ response. Indeed, in experimental 
animals, it has been shown that aP vaccines elicit CD4+ 
which produce large amounts of interleukin (IL)-4 and 
IL-5, but only a small quantity of interferon (INF)-γ, a 
condition that is compatible with a Th2 response [43]. 
By contrast, the administration of wP is associated with 
the production of INF-γ and IL-17, which suggests a 
marked Th1 response [32]. In addition, studies conduct-
ed on children have shown that the production of CD4+ 
cytokines indicative of a Th2 response after primary vac-
cination is markedly higher in aP vaccinees than in those 
vaccinated with wP [44]. 
Although the so-called immunological correlates of 
protection are not as yet available, all these data seem 
to indicate that the long-term protection induced by aP 
vaccines may be lower than that provided by wP, which 
might explain, at least in part, the reemergence of P.
The appearance of genetically modified 
bordetella pertussis strains
While the presence of genetically different strains of Bp 
had already been demonstrated in the period when only 
wP was in use, the phenomenon became more evident 
after the introduction of the aP vaccines [47-49]. Despite 
the lack of official data to correlate this microbiologi-
cal finding with the rise in cases of P, it is nevertheless 
possible that the two phenomena are related. Indeed, it 
does not seem irrational to think that the immunological 
pressure exerted by the vaccine may have favored the 
selection of mutated strains, especially as the circulation 
of these strains has been seen to coincide temporally 
with the widespread use of aP vaccines and the degree 
of vaccination coverage reached in the various coun-
tries [46, 48]. Mutations of the genes that code for the 
proteins contained in the various aP vaccines have often 
been detected. In some cases, such as those of some ge-
netic polymorphisms regarding the genes that code for 
PT, the variation has proved to result in the production 
of a greater quantity of PT, thereby determining more 
severe clinical manifestations in the subjects infected. In 
other cases, such as when one or more genes have been 
deleted, the practical effect has not been definitively 
clarified, though it has been supposed that the very lack 
of a gene that codes for a vaccine protein may limit vac-
cine efficacy [49-53]. 
The most significant data on this issue regard PRN. Bp 
strains lacking this antigen have been detected almost 
everywhere in the world, though with different fre-
quency. A low incidence has been found in Finland [53], 
France  [54], Italy  [55] and Japan  [56], while a high 
frequency has been found in Australia [57], Israel [58] 
and the United States [59]. In the US, 640 (85%) of the 
Tab. III. Studies conducted since the 1990s on the duration of protection induced by acellular pertussis vaccines (aPs).
Author Year Subjects Number of Bp components Estimated duration of protection (years) Country
Simondon [30] 1997 4,181 4 4 Senegal
Tindberg [31] 1999 207 2 10 Sweden
Salmaso [32] 2001 8,432 3 3 Italy
Lugauer [33] 2002 10,271 4 6 Germany
From Wendelboe AM et al., 2015 23, mod.
Tab. IV. Studies conducted since the 1990s on the duration of protection following natural infection by Bp. 
Author Year Subjects
Estimated duration of protection
(years)
Country
Wirsing [34] 1995 369 20 Germany
Miller [35] 1997 Not known (review of studies) 7-10 UK
Versteegh [36] 2002 4 (case series) 3-12 Netherlands
From Wendelboe AM et al., 2015 23, mod.
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753 Bp strains identified in 8 states from March 2011 
to February 2013, a period of high incidence of P, were 
PRN-negative. The hypothesis that deletion of the gene 
coding for PRN may impair the efficacy of vaccines 
that contain this antigen also seems to be supported by 
evidence that PRN-negative Bp strains are able to cause 
very prolonged infections in experimental animals pre-
viously immunized with an aP vaccine containing this 
protein [60]. However, the problem remains open, as the 
data collected in the field are conflicting. Indeed, retro-
spective evaluations of the association between the pres-
ence of PRN-poor strains and a higher incidence of P 
have not always shown a positive correlation between 
the two variables [61].
The composition of acellular vaccines
All the combined vaccines with Bp antigens contain the 
PT antigen. The other components of Bp that are some-
times included are FHA, PRN and FIM types 2 and 3. 
The aP vaccines differ not only in terms of the charac-
teristics of their preparation, such as formulation, com-
bination and concentration in micrograms of the single 
components, but also with regard to their production 
modalities, such as the methods of detoxification and 
purification used. Thus, aP vaccines cannot be compared 
only on the basis of the number of antigenic components 
that they contain, not least because the contribution of 
each antigen to protection is not completely clear [62]. 
Certainly, the indispensable component, which is always 
included in all aP vaccines, is PT; this antigen is directly 
responsible for the development of a protective antibody 
response following immunization. FHA may be of less-
er importance, as it is the strain that is least genetically 
mutated over time, unlike PRN, the mutations of which 
have led to the spread of pertactin-resistent strains. By 
contrast, with regard to the fimbriae, which are also sub-
ject to mutations, there is no evidence that they contrib-
ute to determining immune protection [19, 22, 62]. 
Finally, although no correlates or serological indicators 
of protection regarding P are available, clinical studies 
have shown that the aP vaccines currently utilized elicit 
a robust immune response, with post-vaccination anti-
body levels being higher than on pre-vaccination sero-
logical testing [4-10, 23, 25, 30-33, 40, 43, 44, 62].
Efficacy and effectiveness  
of the various acellular vaccines
Several studies have assessed the efficacy of the aP vac-
cines, i.e. the direct and specific efficacy of a single vac-
cine in preventing P in a given clinical trial [63-75]. Un-
fortunately, however, the possibility of obtaining results 
that are truly capable of revealing possible differences 
among the various aP vaccines is very limited; this is 
not only because long-term evaluations are lacking, but 
also because the criteria for defining P have, in many 
cases, been different, meaning that the types of cases 
enrolled have been different. Moreover, efficacy studies 
have directly compared the aP vaccines most commonly 
administered today, such as the hexavalent, pentavalent 
and quadrivalent vaccines, for example. In addition, 
given that the trend in pertussis is determined by a mul-
tiplicity of factors, such as the duration of the protection 
induced by vaccination, the administration of boosters in 
all age-groups, which is sometimes already implement-
ed, and the risk of natural infection due to the ordinary 
circulation of Bp, it seems somewhat simplistic to carry 
out efficacy assessments alone. Rather, in order to draw 
up the most appropriate strategies for the control and 
prevention of P, it is important to obtain evidence from 
studies that assess true efficacy in the field, i.e. effective-
ness studies that take into account the contribution of all 
these factors. Indeed, clinical trials are closed, isolated 
experiments; as such, they do not take into account such 
factors as the burden and epidemiology of the disease in 
a given geographical area, and how these vary over time; 
nor do they consider the actual implementation of vac-
cination programs in a given country, i.e. whether cov-
erage targets have been reached, whether booster doses 
are administered, whether vaccination is scheduled for 
healthcare workers and pregnant women, and so on. 
Thus, only studies of effectiveness, i.e. the efficacy of 
vaccination in real life, can yield real-world evidence, 
and are therefore essential in order to help policy-makers 
to plan the most appropriate strategy for the control of 
pertussis in their own countries.
Table V reports the trials which have evaluated the effi-
cacy of aP vaccines and the surveillance studies in which 
their effectiveness has been assessed.
Efficacy studies
Several controlled clinical trials have evaluated the ef-
ficacy of aP vaccines in preventing pertussis, according 
to the definition used in the literature and that proposed 
by the WHO [74].
In a study by Greco et al. [7], the efficacy of the 3-com-
ponent aP vaccine was 84% (95%  confidence inter-
val [CI] 75.8-89.4). In a trial conducted by Gustafsson et 
al. [8], in which two aPs were evaluated, the efficacy of 
the 5-component vaccine was 85% (95% CI 80.6-88.8), 
while that of the 2-component vaccine was markedly 
lower: 59% (95% CI 50.9-65.9). This low efficacy score 
was probably one of the reasons why the 2-component 
vaccine analyzed in this study was not subsequently 
registered and was therefore never used in vaccination 
programs. In a trial conducted by Simondon et al. [63], 
in which another 2-component vaccine was used, ef-
ficacy was 85% (95% CI 66-93); this result was suffi-
cient for approval in the regulatory setting and for im-
plementation in vaccination programs. Finally, in a trial 
by Trollfors et al., in which a single-component (the PT 
antigen) vaccine was used, efficacy proved to be 71%; 
this vaccine is still in use today, especially in northern 
Europe [65]. In sum, with the exception of the 2-com-
ponent vaccine that failed to be registered owing to its 
low efficacy, all the other aP vaccines currently available 
have displayed high efficacy in the various clinical trials, 
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and have consequently been used in national vaccina-
tion programs. These results show that the efficacy of aP 
vaccines does not depend on the number of Bp antigen 
components that they contain; rather, it is determined by 
other factors, which may be the formulation and produc-
tion modalities and the methods of detoxification and 
purification.
Zhang et al.  [64] conducted a review of the clinical 
trials (up to 2014) which had compared the efficacy of 
wP and aP vaccines, these latter containing from 1 to 5 
components. Owing to the methodology adopted, this 
review also included studies involving vaccines that 
are no longer produced or utilized in national vaccina-
tion programs, having been replaced over the years by 
vaccines with better efficacy profiles. One of the tri-
als included in the review was that of the above-men-
tioned 2-component vaccine that was never registered, 
presumably owing to the low efficacy observed  [8]. 
By contrast, the review did not include the trial of the 
other 2-component vaccine [63] – which is commonly 
used today – as it had been conducted according to a 
methodology that did not fall within the inclusion cri-
teria set by the review. 
Moreover, as direct efficacy studies of the aP vaccines 
commonly used today, such as hexavalent and pentava-
lent vaccines for pediatric vaccinations, are not avail-
able, indirect comparisons have been made on the basis 
of clinical trials of combined vaccines, for both pedi-
atric and adult use, with different valences, giving rise 
to a heterogeneity bias. A further bias stems from the 
methodology used in the clinical trials, particularly with 
regard to the clinical case definition of pertussis. These 
limitations and biases were identified and described by 
the authors of the above-mentioned review. Neverthe-
less, the conclusions regarding the possible differences 
in efficacy among aP vaccines containing different num-
bers of antigens, and the differences between these vac-
cines and wP vaccines, are inevitably distorted.
Effectiveness studies
Various national epidemiological surveillance studies 
have evaluated the effectiveness of anti-P vaccination 
through the analysis of actual experience in the field. In 
general, all the currently available 1-, 2-, 3- and 5-com-
ponent aP vaccines have displayed high effectiveness, 
yielding a marked reduction in the incidence of pertus-
sis, thanks also to the elevated coverage rates achieved. 
For example, national epidemiological surveillance in 
Sweden, which began in the year when aP vaccines were 
introduced (1996), has shown that these vaccines have 
great effectiveness; indeed, the incidence of P fell from 
its pre-1996 level of over 100 cases/100,000 residents to 
below 10 cases/100,000 residents in the period between 
2010 and the last measurement in 2016. Moreover, in 
an analysis stratified by region and type of vaccine used 
(1-, 2-, 3- and 5-component), no differences in incidence 
rates emerged; this indicates that P is effectively under 
control throughout the nation, regardless of the type of 
aP vaccine used. Notably, from 1996 to today, the prima-
ry vaccination coverage rates in infants (3 doses) have 
always been 97-98%, i.e. above the 95% target for this 
age-group [65].
In Denmark, a single-component (PT) aP vaccine has 
been used since 1995; as revealed by national surveil-
lance, pertussis is well controlled. Indeed, up to the last 
survey in 2013, the incidence of P always remained be-
low 10  cases/100,000 residents, with the exception of 
2002, when an epidemic outbreak raised the incidence to 
36 cases/100,000. In this case, too, primary vaccination 
coverage in infants (3 doses) remained particularly high: 
90-99% in the period 1995-2005, 58-91% in the period 
2006-2013  [66]. In the period 2013-2016 the pertussis 
incidence in Denmark was 10.8 cases/100,000 inhabit-
ants [19].
In general, as described in the latest ECDC report, 
in 2015 the incidence of P in the EU/EEA countries 
was 9  cases/100,000, a similar value to the preced-
ing years. As expected, it emerged from the various 
national reports that the incidence was higher among 
children aged  <  1  year: 73.1  cases/100,000; 85% of 
these cases involved infants below 6 months of age. 
Precisely on account of this latter finding, the ECDC 
has recommended that the EU/EEA countries increase 
their commitment to offering vaccination to pregnant 
women, since an infant up to the age of 6 months has 
not yet developed the immunity induced by primary 
vaccination [19].
Surveillance programs conducted in some non-EU/EEA 
countries, such as the USA  [67], Canada  [68] and Ja-
pan  [56], have also revealed the great effectiveness of 
aP vaccines in preventing and controlling pertussis, with 
the incidence of the disease declining to less than 10 cas-
es/100,000, regardless of which aP vaccine is used.
Thus, the WHO’s latest position paper on pertussis vac-
cines states that possible differences among aP vaccines 
in terms of efficacy, as reported by some trials and re-
Tab. V. Efficacy trials and surveillance studies of the effectiveness of 
acellular pertussis vaccines (aPs).
Author or 
Country
N. antigen 
components
Efficacy (%) or effectiveness 
(incidence)
Greco [7] 3 84%
Gustafsson [8] 2*; 5 59%*; 85%
Simondon [63] 2 85%
Trollfors [75] 1 71%
Sweden [65] 1, 2, 3, 5
From > 100 cases/100,000 
to < 10 cases/100,000 
residents
Denmark [66] 1
From > 100 cases/100,000 
to < 10 cases/100,000 
residents
EU/EEA 
countries [19]
1, 2, 3, 5
From > 100 cases/100,000 
to < 10 cases/100,000 
residents
Non-EU/EEA 
countries:
USA [67], 
Canada [68], 
Japan [56]
1, 2, 3, 5
From > 100 cases/100,000 
to < 10 cases/100,000 
residents
*: 2-component vaccine not registered and never used in national vac-
cination programs.
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views, should be interpreted with caution, in that such 
findings are contradicted by national surveillance pro-
grams and studies of real-world evidence, in which all 
aP vaccines have displayed great effectiveness in pre-
venting and controlling pertussis [69].
Strategy for preventing  
and controlling pertussis (p)
Immunity to P, whether conferred by vaccination or by 
natural infection, wanes over time; the need to adminis-
ter booster vaccine doses is therefore essential. Indeed, 
although the clinical manifestations of the disease be-
come less severe with age, an infected individual may 
infect infants in their first months of life, when the dis-
ease is clinically more serious. 
It has been amply demonstrated that the prevention 
and control of pertussis depend on the achievement of 
high vaccination coverage rates in the whole population 
through the adoption of a vaccination calendar with at 
least the following features [62, 70, 76]:
• scheduled primary vaccination for infants, and ad-
ministration of a booster dose at pediatric concentra-
tion in preschool children;
• a booster dose in adolescents and adults (aged 
20 years or more) to be repeated every 10 years, with 
reduced-concentration vaccines in adults.
The main positions and recommendations of official au-
thorities and international experts are described in Ta-
ble VI [18, 62, 69, 70, 74, 77].
In addition, recent studies have highlighted the impor-
tance of vaccinating specific groups, such as healthcare 
workers and pregnant women. Regarding this latter 
group, vaccination with an adult-formulation vaccine 
in the 3rd trimester of pregnancy confers the protection 
of the mother’s antibodies upon the newborn in the first 
months of life, i.e. before primary vaccination – a pe-
riod when infection by Bp may be extremely serious. 
These studies have revealed an effectiveness of over 
90%, which means that more than 9 out of 10 cases of 
pertussis in infants in the first months of life could be 
avoided if women were vaccinated in the 3rd trimester of 
pregnancy [71, 72]. 
Several countries have already drawn up official recom-
mendations that include the above-mentioned interven-
tions. Nevertheless, it is necessary to strengthen the com-
mitment to implement initiatives aimed at raising public 
awareness and promoting “vaccine confidence” in the 
population, in order to achieve full adherence to the rec-
ommendations and to reach vaccination coverage targets. 
Italy, for example, has drawn up the National Vaccina-
tion Prevention Plan 2017-2019 (PNPV)  [73], which 
not only envisions both the primary vaccination of in-
fants against pertussis and the administration of periodic 
booster doses at all ages, but also targets specific groups 
for vaccination, such as healthcare workers and preg-
nant women. However, some highly sensitive coverage 
objectives, such as the vaccination of pregnant women, 
are still far from being reached, and in some regions are 
not even actively promoted. By contrast, the vaccination 
coverage of children of preschool age, has either reached 
or is close to reaching the 95% objective set by the PN-
PV for this age-group.
Conclusions
On the basis of the clinical trials, effectiveness studies 
and real-world evidence reported in the literature, the 
following conclusions may be drawn with regard to all 
Tab. VI. Positions and recommendations of official authorities and international experts on pertussis vaccinations.
WHO, Pertussis vaccines position 
paper [76]
Surveillance studies in countries where aP vaccines (including 1- and 2-component aPs) are 
used, have shown high levels of effectiveness in preventing pertussis.
All aP vaccines have displayed high levels of effectiveness in preventing pertussis, regardless 
of the number of Bp antigens they contain.
WHO, Pertussis vaccines position 
paper [69]
Differences in efficacy among aP vaccines reported by trials and reviews must be interpreted 
with caution, as all aP vaccines have shown high effectiveness in national surveillance 
programs and studies of real-world evidence
WHO SAGE Working Group [18]
There is insufficient evidence to conclude that one type of aP vaccine is superior to another. 
However, the available data underline the importance of reaching and maintaining high 
coverage rates and of implementing appropriate vaccination schedules.
CDC Pink Book [77]
The efficacy of the various aP vaccines varies from 80 to 85%, while their respective 
confidence intervals overlap, suggesting that no aP vaccine is significantly more efficacious 
than the others.
Martinon-Torres [70]
To achieve high coverage rates in the population, it is necessary to implement a vaccination 
strategy that includes both the primary vaccination of infants and booster administration in 
preschool children, adolescents and adults, with particular emphasis on the vaccination of 
pregnant women.
Gabutti [62]
It is important to bear in mind that the use of the current polyvalent aP vaccines has enabled 
high coverage rates to be achieved and maintained, regardless of vaccine type and the 
number of Bp components it contains, which is the key factor in successful intervention 
against pertussis.
Zhang [74]
Reviewing clinical efficacy trials alone may yield a limited picture of the benefits of aP 
vaccines, not least because of differences among the trials themselves and possible biases.
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the currently available aP vaccines, regardless of the 
number of Bp components they contain:
• they have proved to be highly safe and immunogen-
ic, eliciting a robust antibody response in vaccines, 
though the correlates of sero-protection against P are 
not known;
• their efficacy has been demonstrated in clinical trials, 
i.e. closed experimental studies;
• their effectiveness has been demonstrated by epide-
miological surveillance and studies of real-world evi-
dence, i.e. actual experience in the field;
• in countries where wP vaccines have been replaced 
by aP vaccines, the control of P has proved highly 
effective;
• strategies for the control and prevention of P must 
involve the achievement and maintenance of high 
vaccination coverage rates in the entire population.
Nevertheless, recent evidence has revealed some possi-
ble limitations of the currently available aP vaccines, re-
gardless of the number of Bp components they contain:
• the fact that the duration of protection is suboptimal 
means that Bp carriage cannot be eliminated;
• there is a higher risk of the onset of P in a non-negli-
gible number of subjects, including those who were 
last vaccinated only a few years earlier; 
• booster doses should probably be more numerous 
and more closely spaced than is currently the case;
• the protection elicited is not associated to a Th1/
Th17 response, which is probably necessary in order 
to achieve more efficacious protection; 
• Bp has developed vaccine resistance as a result of 
several antigenic mutations.
It is to be hoped that future developments will result in 
the production of pertussis vaccines whose antigenic for-
mulation also takes into account Bp mutations and the 
possibility of eliciting a Th1/Th17 immune response. In 
the meantime, however, the results of effectiveness stud-
ies and real-world evidence must be taken into account, 
in order to work out the most suitable vaccination strate-
gies for each specific epidemiological and geographical 
context.
In general, in countries where aP vaccines are used, as 
those in Europe but not only, the following interventions 
and objectives for the prevention of P should be recom-
mended:
• the achievement and maintenance of high vaccina-
tion coverage rates at all ages;
• primary vaccination of infants in the first year of life: 
a schedule beginning at 2 months and using com-
bined vaccines, such as hexavalent vaccines, in order 
to exploit the synergic effect and achieve important 
results in the prevention of other diseases, too;
• administration of booster doses in childhood at 
5-6 years of age, in adolescence at 12-18 years and in 
adulthood every 10 years throughout life, and there-
fore also in the elderly;
• increasing coverage among healthcare workers;
• anti-pertussis vaccination during pregnancy, in or-
der to protect the newborn during the first months of 
life; this would close the gap which exists in many 
countries between the official recommendations and 
actual implementation.
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